Cordis

The Cordish Companies Announces Construction to Begin on Three Light Luxury Apartments in May, Midland Lofts Summer 2021 in the Kansas City Power & Light District

Thursday, April 8, 2021 - 2:00pm

Following the success of its predecessors, One Light and Two Light Luxury Apartments, which have remained 95% occupied throughout the pandemic, Three Light Luxury Apartments will introduce the next stage of urban luxury living in the Power & Light District in downtown Kansas City.

Key Points: 
  • Following the success of its predecessors, One Light and Two Light Luxury Apartments, which have remained 95% occupied throughout the pandemic, Three Light Luxury Apartments will introduce the next stage of urban luxury living in the Power & Light District in downtown Kansas City.
  • "From the vision the company had with the Power & Light District, to One Light, Two Light and now Three Light Luxury Apartments, we are grateful for the relationship we have with The Cordish Companies and the impact the company has had on Kansas City.
  • "The Cordish Companies," "The Cordish Company" and "Cordish" are trademarks used under license by independent corporations, legal liability companies and partnerships ("Cordish Entities").
  • The Kansas City Power & Light District is a vibrant multi-city block neighborhood in the heart of downtown Kansas City that is redefining the city from its skyline to its sidewalks.

Cardiovascular Systems, Inc. to Participate at the 20th Annual Needham Healthcare Conference

Wednesday, March 24, 2021 - 11:00am

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the 20th Annual Needham Healthcare conference on Tuesday, April 13, 2021.

Key Points: 
  • Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the 20th Annual Needham Healthcare conference on Tuesday, April 13, 2021.
  • A webcast of the presentation will be made available on CSI's website.
  • Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.
  • For additional information, please visit www.csi360.com and connect on Twitter @csi360.

Cardiovascular Systems, Inc. Announces Acquisition of Peripheral Support Catheters From WavePoint Medical, LLC

Monday, March 22, 2021 - 1:00pm

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) announced today that it has acquired a line of peripheral support catheters from WavePoint Medical, LLC.

Key Points: 
  • Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) announced today that it has acquired a line of peripheral support catheters from WavePoint Medical, LLC.
  • Peripheral support catheters are used during peripheral vascular intervention (PVI) procedures for guidewire support to enable lesion crossing, as well as for guidewire exchanges.
  • Scott R. Ward, Chairman, President and Chief Executive Officer of CSI, said, With the acquisition of these peripheral support catheters, CSI will soon offer a complete portfolio of products for the treatment of peripheral artery disease, including atherectomy, balloon catheters, guidewires, support catheters and embolic protection.
  • WavePoint Medical LLC, a MedVenture Holdings portfolio company, is a Utah based medical device development company focused on high-performance micro-catheters for the interventional cardiovascular markets.

ViewRay Announces Departure of Chief Operating Officer

Monday, March 15, 2021 - 1:00pm

CLEVELAND, March 15, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) ("the Company") today announced that Shahriar Matin, Chief Operating Officer, will leave the Company effective March 31, 2021.

Key Points: 
  • CLEVELAND, March 15, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) ("the Company") today announced that Shahriar Matin, Chief Operating Officer, will leave the Company effective March 31, 2021.
  • Matin was named Chief Executive Officer designate of Cordis in its recently announced divestiture from Cardinal Health to private equity firm Hellman & Friedman.
  • "It has been a privilege to work alongside the ViewRay team, and I believe that MRIdian is unequivocally the future of radiation oncology," said Shahriar Matin, Chief Operating Officer.
  • I wish him continued success and hearty congratulations in his new endeavors," said President and Chief Executive Officer Scott Drake.

DHR Health and Cipherome to Pioneer Personalized Medicine Project in Patients Undergoing Percutaneous Coronary Interventions

Sunday, February 28, 2021 - 11:00pm

After a stroke or heart attack, the standard treatment is Percutaneous Coronary Intervention (PCI), or stent placement.

Key Points: 
  • After a stroke or heart attack, the standard treatment is Percutaneous Coronary Intervention (PCI), or stent placement.
  • Recent studies show the possibility of an 80-percent reduction in PCI 90-day complications by using a patients personalized genetic information.
  • About DHR Health Institute for Research and Development:
    DHR Health Institute for Research & Development is a nonprofit organized under the Federal Internal Revenue Service Code 501(c)(3).
  • DHR Health Institute for Research and Development leads the way for innovative state-of-the-art clinical research in the Rio Grande Valley.

BioCardia Announces Clinical Leadership Changes

Wednesday, February 17, 2021 - 1:30pm

SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies,today announced clinical leadership changes.

Key Points: 
  • SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies,today announced clinical leadership changes.
  • Ms. Debby Holmes-Higgin who has been with the Company for more than three years will continue to serve as Vice President of Clinical with expanded responsibilities.
  • Dr. Stoll has extensive clinical experience having been most recently the Chief Medical Officer at Biosensors International, GE Healthcare, and Cordis, Johnson & Johnson.
  • BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

The Cordish Companies Proudly Celebrates The Grand Opening Of Live! Casino & Hotel Philadelphia

Friday, February 12, 2021 - 4:18pm

Casino & Hotel Philadelphia, the new world-class gaming, hotel, dining and entertainment destination located in the heart of the Philadelphia Stadium District.

Key Points: 
  • Casino & Hotel Philadelphia, the new world-class gaming, hotel, dining and entertainment destination located in the heart of the Philadelphia Stadium District.
  • Casino brand into the great City of Philadelphia," said Reed Cordish, Principal of The Cordish Companies.
  • Casino & Hotel Philadelphia to South Philadelphia and the entire Greater Philadelphia Region," Philadelphia City Councilmember Kenyatta Johnson (Second District) said.
  • "The Cordish Companies," "The Cordish Company" and "Cordish" are trademarks used under license by independent corporations, legal liability companies and partnerships ("Cordish Entities").

India Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents - ResearchAndMarkets.com

Monday, January 25, 2021 - 3:11pm

The "India Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's offering.
  • "India Interventional Cardiology Market Outlook to 2025" is a comprehensive databook report, covering key market data on the India Interventional Cardiology market.
  • The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Cardiac Catheters, Coronary Guidewires, Coronary Stents, Intravascular Ultrasound Systems (IVUS) and PTCA Balloon Catheters.
  • Global corporate-level profiles of key companies operating within the India Interventional Cardiology Market.

Global PTCA Balloon Catheters Devices Pipeline Assessment 2020: Stage of Development, Segment, Territory, Regulatory Path, Estimated Approval Date, Ongoing Clinical Trials - ResearchAndMarkets.com

Friday, January 15, 2021 - 10:37am

The "PTCA Balloon Catheters - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PTCA Balloon Catheters - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.
  • "PTCA Balloon Catheters-Medical Devices Pipeline Assessment, 2020" Percutaneous Transluminal Coronary Angioplasty (PTCA) is a procedure that helps restore blood flow to a blocked coronary artery without the requirement of open heart surgery.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    In-depth analysis of the product's current stage of development, territory and estimated launch date

EU5 Interventional Cardiology Market Analysis and Forecasts to 2025 - ResearchAndMarkets.com

Tuesday, January 5, 2021 - 9:26am

The "EU5 Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "EU5 Interventional Cardiology Market Outlook to 2025 - Cardiac Catheters, Coronary Guidewires, Coronary Stents and Others" report has been added to ResearchAndMarkets.com's offering.
  • This is a comprehensive databook report, covering key market data on the EU5 Interventional Cardiology market.
  • 2019 company share and distribution share data for Interventional Cardiology Market.
  • Global corporate-level profiles of key companies operating within the EU5 Interventional Cardiology Market.